Browsing Tag
Australia
722 posts
Australia and Fiji sign mutual defence alliance as Pacific security competition intensifies
The Ocean of Peace Alliance creates a mutual defence commitment between Australia and Fiji, while the separate Vuvale Union expands cooperation across security, development, policing and economic resilience.
PEXA Group (ASX: PXA) crashes 21% as IPART fee cut puts A$70m revenue at risk
PEXA dominates digital property settlements, but IPART wants A$70m less regulated revenue. Its biggest competitive moat has become the risk.
PEXA (ASX: PXA) shares plunge 21% as draft fee review targets A$70m of FY28 revenue
PEXA Group’s Australian platform remains operationally dominant, but a proposed regulatory reset has forced investors to reconsider how much of that dominance can translate into future earnings.
FIFA World Cup 2026: Salah Panenka sends Egypt past Australia 4-2 on penalties
Egypt beat Australia 4-2 on penalties after a 1-1 draw as Mohamed Salah’s Panenka sealed a historic FIFA World Cup 2026 knockout victory.
European Lithium (ASX:EUR) trades below CRML deal value as scheme risk takes centre stage
European Lithium trades below its CRML scheme value, but the payout moves with Nasdaq. The apparent discount comes with real completion risk.
Accent Group (ASX:AX1) trades above Frasers’ A$0.65 bid as investors await the next move
Frasers wants Accent Group at A$0.65, but AX1 trades above the bid. The market is pricing a higher offer, a turnaround, or both.
Stakk (ASX:SKK) halts on a major acquisition as its A$26m revenue story faces a dilution test
Stakk has reached a A$26m revenue run-rate, then halted for an acquisition and capital raise. The deal must justify its dilution risk.
Racura Oncology (ASX:RAC): Will HARNESS-1 reset its valuation?
Racura Oncology has funded three cancer trials, but RAC shares remain far below their high. HARNESS-1 must now turn clinical progress into evidence.
CMC Markets (LSE: CMCX) shares hit record high as B2B growth triggers major FY2027 upgrade
CMC Markets has raised FY2027 income guidance to at least ÂŁ550 million, signalling that its institutional platform strategy is scaling faster and generating substantially stronger operating leverage than investors expected.
Neuren Pharmaceuticals (ASX: NEU) jumped 45% in two sessions, but how much DAYBUE upside remains?
DAYBUE’s EU breakthrough sent NEU up 45% in two sessions. The harder test is whether royalties and NNZ-2591 justify A$2.25 billion.